# Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults

> **NCT00814489** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Streptococcus Pneumoniae
- Haemophilus Influenzae

## Interventions

- **BIOLOGICAL:** GSK2231395A
- **BIOLOGICAL:** Engerix-B

## Key facts

- **NCT ID:** NCT00814489
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01-08
- **Primary completion:** 2009-05-04
- **Final completion:** 2010-06-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00814489

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00814489, "Evaluation of Non-typable Haemophilus Influenzae and Pneumococcal Protein Vaccine Formulations in Young Adults". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT00814489. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*